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Abstract.  Fibrinogen inhibited  ~25I-high molecular 
weight kininogen (HMWK) binding and displaced 
bound J25I-HMWK from neutrophils.  Studies were per- 
formed to determine whether fibrinogen could bind to 
human neutrophils and to describe the HMWK-fibrin- 
ogen interaction on cellular surfaces.  At 4°C,  the 
binding of ~2H-fibrinogen to neutrophils  reached a pla- 
teau by 30 min and did not decrease. At 23 and 37°C, 
the amount of t25I-fibrinogen bound peaked by 4 min 
and then decreased over time because of proteolysis of 
fibrinogen by human neutrophil  elastase (HNE).  Zn++ 
(50 #M) was required for binding of ~25I-fibrinogen to 
neutrophils at 4°C and the addition of Ca  ++ (2 mM) 
increased the binding twofold. Excess unlabeled fibrin- 
ogen or HMWK completely inhibited binding of 
~25I-fibrinogen. Fibronectin degradation products 
(FNDP) partially  inhibited binding,  but prekallikrein 
and factor XII did not.  The binding of ~25I-fibrinogen 
at 4°C was reversible with a 50-fold molar excess of 
fibrinogen or HMWK. Binding of ~25I-fibrinogen, at a 
concentration  range of 5-200/~g/ml  of added radio- 
ligand,  was saturable with an apparent Kd of 0.17/~M 
and  140,000  sites/cell.  The binding of ~25I-fibrinogen to 
neutrophils was not inhibited by the peptide RGDS de- 
rived from the ot chain of fibrinogen or by the mAb 
10E5 to the platelet glycoprotein IIb/IIIa heterodimer. 
Fibrinogen binding was inhibited by a 3,-chain  peptide 
CYGHHLGGAKQAGDV and by mAb OKM1 but was 
not inhibited by OKM10, an mAb to a different do- 
main of the adhesion glycoprotein Mac-1  (complement 
receptor type 3 [CR3]).  HMWK binding to neutrophils 
was not inhibited by OKM1.  These observations were 
consistent with a  further finding that fibrinogen is a 
noncompetitive inhibitor of tzSI-HMWK binding to 
neutrophils.  Fibrinogen binding to ADP-stimulated 
platelets was increased twofold by Zn  +÷ (50 #M) and 
was inhibited by HMWK. These studies indicate that 
fibrinogen specifically binds to the C3R receptor on 
the neutrophil  surface through the carboxy terminal  of 
the 3,-chain  and that HMWK interferes with the bind- 
ing of fibrinogen to integrins  on both neutrophils and 
activated platelets. 
H 
UMAN kininogens  are multifunctional  proteins  (48) 
coded for by a gene containing  11 exons (58).  The 
first nine are expressed as a heavy chain-containing 
domain with cysteine protease inhibitory activity (43). Exon 
10 codes for bradykinin and 12 additional amino acids which, 
like domains 1-9, are common to both high (120,000) and low 
(67,000) molecular weight kininogen (HMWK and LMWK, 
respectively).~  By differential  splicing  of the mRNA one 
obtains HMWK with the rest of domain 10, specifying a light 
chain (56 kD) with surface binding (51) and prekallikrein  and 
factor XI binding sites (57). Together, these domains confer 
on HMWK the ability to accelerate activation of the contact 
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balanced salt solution; HMWK, high molecular weight kininogen; HNE, 
human neutrophil elastase;  LMWK, low molecular weight  kininogen. 
phase of blood coagulation.  Alternatively,  a different splic- 
ing site allows attachment  of domain 11, supplying an alter- 
nate light chain which has no known biologic activity and is 
contained  within  LMWK. 
Vroman et al. (60) noted that HMWK can displace fibrino- 
gen from artificial  hydrophilic  surfaces such as glass.  This 
effect is specifically due to the light chain of HMWK since 
purified  LMWK did not alter the surface expression of fi- 
brinogen (47). To date no evidence exists to indicate whether 
such a phenomenon exists on biologic surfaces.  Fibrinogen 
has been shown to specifically bind to platelets (7, 31) as well 
as to integrins  on endothelial  cells (14) and monocytes (1). 
Similarly, HMWK has been demonstrated  to bind to platelets 
(19, 20),  neutrophils  (21), and  endothelial  cells (49).  The 
binding of fibrinogen to platelet membrane receptors (7, 28, 
35) and to neutrophil  surfaces (8) may result in the aggrega- 
tion of these cells. Since neutrophils can ingest fibrin (5), ac- 
cumulate  within  thrombi,  and penetrate  preformed blood 
clots (22),  we sought  to determine whether ~25I-fibrinogen 
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We also investigated  whether HMWK can modify the inter- 
action  of fibrinogen with neutrophils  and platelets.  These 
studies  demonstrate  that tzq-fibrinogen binds to complement 
receptor type 3 (CR3) on human neutrophils in a specific, re- 
versible, and saturable  manner.  Furthermore, HMWK and 
fibrinogen reciprocally inhibit binding of the other protein to 
both the neutrophil and activated  platelet surface. 
Materials and Methods 
Materials 
Iodogen (chloramide,  1,3,4,6-tetrachloro-3 cz, 6 ~x-diphenyl-glycoluril) was 
obtained  from  Pierce  Chemical  Co.  (Rockford,  IL).  125I-Na (50  mCi/ 
mmol) was obtained from ICN  Pharmaceuticals  (Irvine,  CA).  N-Butyl- 
phthalate was obtained from Fisher Scientific Co. (Pittsburgh, PA). Apiezion 
oil (a mixture of silicon oils) was obtained from Apiezion Products Limited 
(London, England). Hanks' balanced salt solution (HBSS) free of calcium 
chloride, magnesium sulfate, and magnesium chloride was obtained from 
Gibeo Laboratories (Grand Island, NY).  Ficoll-Paque was obtained from 
Pharmacia  Fine Chemicals  (Piscataway,  NJ).  Methoxysuccinyl-Ala-Ala- 
Pro-Val-p-nitroanilide and phorbol myristate acetate were purchased from 
Sigma Chemical Co.  (St.  Louis,  MO). 
Plasma and Neutrophils 
Pooled normal plasma (lot 6130) was purchased from George King Biomed- 
ical Inc.  (Overland Park,  KS).  Total kininogen-deficient plasma (plasma 
deficient in both HMWK and LMWK) and neutrophils deficient in HMWK 
were donated by Mrs. Williams (12). Normal donors were young males and 
females (age 21-45 yr) who were not on any medication and had given their 
written, informed consent. 
Neutrophil Isolation 
Human neutrophils were isolated from whole blood anticoagulated with 0.1 
vol acid-citrate-dextrose by sedimentation at 1 g  in dextran (1.5%). After 
sedimentation, the upper leukocyte-enriched plasma was gently layered over 
15 ml of FicoU-paque (each 100 ml contained 5.7 g Ficoll 400 and 9 g so- 
dium ditrizoate sodium) and centrifuged at 400 g for 45 min at 23°C. The 
cell pellet was resuspended in an erythrocyte lysis buffer composed of 155 
mM NH4CI, 2.7 mM KHCO3, and 3.7 mM EDTA, pH 7.4. The suspension 
was centrifuged at 400 g for 20 min, and the cell pellet was washed three 
times in excess saline, pH 7.4 (8). After the final saline wash, the cells were 
resuspended in HBSS without magnesium or calcium (107-109 cells/ml). 
Cell count and purity were determined after dilution in Turk's solution (3 % 
glacial acetic acid and 1% crystal violet). This procedure yielded ,,08  x 
l0  s neutrophils/U whole blood, and the cells were isolated to 96% purity. 
Contaminating cells were platelets, not monocytes, and could not contribute 
>1.5% of the fibrinogen binding sites. In certain experiments the isolated 
neutrophils were stimulated as previously described (61) by incubating 107 
cells/nil with PMA (1 #M) at 25*C for 10 min. Activation was followed by 
measuring the release of human neutrophil elastase (HNE) into the superna- 
tant (61). 
Platelet Isolation 
Platelets were prepared from freshly collected blood in acid-citrate-dextrose 
by the method of Mustard et al. (33). The final platelet suspension was made 
in a  Tyrode's solution (12 mM NaHCO3,  0.3 mM Na2H2PO4,  2.65  mM 
KCI, 137 mM NaCI, 12.5 mM glucose, and 3.5 mg/ml BSA, pH 7.35, con- 
taining 2  mM CaCI2 and 1 mM MgCI2). 
Proteins 
HMWK was purified using a modified method (20) of Kcrbiriou and Griffin 
(26). Under reducing conditions, this preparation of HMWK on 7.5 % poly- 
acrylamide with SDS was primarily a single band with a molecular mass 
of 120 kD, >98% purity, and a specific activity of 12-20 U/ml. Purified 
HMWK  was  radiolabeled with  12SI-Na using Iodogen by the method of 
Fraker and Speck (16)  under conditions previously described (46).  The 
specific radioactivity of the protein varied from 1-3.5 #Ci/#g with >75% 
of the molecules of HMWK being iodinated. The radiolabeled protein re- 
tained >95% of its procoagulant activity as well as its antigenic properties, 
as previously reported (20). Purified factor XII (70 #g/ml) and prekallikrein 
(1 mg/ml) were provided by Dr. Robin Pixley (Temple University, Philadel- 
phia, PA).  Foy, an inhibitor of cathepsin G but not HNE (18), wag kindly 
provided by Dr. Frederick Kueppers (Temple University, Philadelphia, PA). 
Eglin, an inhibitor of both cathepsin G and HNE, was generously provided 
by Dr.  Hans-Peter Schnebli, (Ciba-Geigy AG, Basel,  Switzerland)  (53). 
HNE was purified to homogeneity by the procedure of Baugh and Travis 
(6). Human fibrinogen (Kabi AB, Stockholm, Sweden) was further purified 
by ammonium sulfate precipitation (34), radiolabeled with 125I-Na with the 
aid of Enzymo beads (Pierce Chemical Co.) or Bio-Rad-beads (Bio-Rad 
Laboratories, Richmond, CA), and separated from free iodine by gel filtra- 
tion using a  Sephadex G25 column. The radiolabeled fibrinogen demon- 
strated 95 % clottability. Fibronectin degradation products (FNDPs) were 
obtained from Dr. Andrei Budzynski (Temple University, Philadelphia, PA) 
and have been characterized previously (61).  A  peptide,  CYGQQHHLG- 
GAKQAGDV,  modeled from a portion of the "r chain of fibrinogen, was pur- 
chased from Peninsula Laboratories,  Inc. (Belmont, CA). 
Antibodies 
A monospecific polyclonal neutralizing antibody to HNE (24) was gener- 
ously provided by Dr.  Frederick Kueppers (Temple University, Philadel- 
phia, PA). The mAb 10E5 was a generous gift of Dr. Barry Coller (State 
University of New York at Stony Brook, Stony Brook, NY) (11). The mAb 
OKM1  was purchased  from Ortho  Diagnostic  Systems  Inc.  (Westwood, 
MA) (59). The mAb IMY8 was purchased from Coulter Electronics Inc. 
(Hialeah,  FL).  The mAb OKMI0  was  obtained from Ortho  Diagnostic 
Systems Inc. (courtesy of Dr.  Pat Rao) in the form of IgG purified using 
protein A. 
Effect of  Zn  ÷÷ on the Elution of  Fibrinogen from 
HPLC Column 
To investigate the effect of Zn  ++ on the physical state of fibrinogen, the elu- 
tion patterns of fibrinogen from HPLC  column equilibrated either with 
Z++-free  Tyrode's  buffer or  with  Tyrode's buffer containing Zn  ++ were 
compared.  Zn++-free Tyrode's  solution was obtained by  passage  over a 
Chelex-100 resin (Bio-Rad Laboratories). A TSK4000 size exclusion HPLC 
column (Pharmacia Fine Chemicals) was equilibrated with normal Tyrode's 
solution containing 0.3%  albumin in the absence and presence of 50 #M 
ZnSO4.  The column in Tyrode's buffer in the presence and absence was 
calibrated with molecular mass standards: thyroglobulin (664 kD), ferritin 
(440 kD),  catalase (232 kD),  and aldolase (158  kD).  Purified fibrinogen 
(Kabi AB) was applied to the column with each buffer, and the elution 
profiles were recorded. 
Assays 
HMWK proeoagulant activity was measured by a one-stage kaolin activa- 
tion assay (12) using total kininogen-dcficient plasma as substrate. Samples 
were  compared  with  a  simultaneously  performed  standard  curve  from 
pooled  normal human plasma diluted  1:10 to  1:1,000  with 0.01 M  Tris, 
0.15 M NaCI, pH 7.4. One unit was defined as that amount of procoagulant 
activity in 1 ml of pooled normal plasma. HNE activity was measured by 
a chromogenic assay using the substrate, methoxysuccinyl-Ala-Ala-Pro-Val- 
p-nitro-anilide (61). 
Binding Experiments 
In all binding experiments,  neutrophils were at a  final concentration of 
107/ml.  In a typical binding experiment, 300-400 #1 of washed neutrophils 
in HBSS without added calcium or magnesium, pH 7.4, were incubated at 
4°C without stirring in a 1.5-ml conical polypmpylene centrifuge tube (Sar- 
stedt, Inc., Princeton, NJ). 400 ~g 125I-fibrinogen or 1 ~g t25I-HMWK as 
well as additions were added to yield a total volume of 350-450 #1. After 
variable incubations for different experiments, 50-~1 aliquots were removed 
(in triplicate) for each experimental point. Each sample was centrifuged at 
9,650 g  at 23°C  in a  microfuge  (model B;  Beckman Instruments,  Inc., 
Fuilerton,  CA)  for 2  min through a  200-#1  mixture of silicon oils (1:9 
Apiezion/N-botyl-phthalate)  in polypropylene  microsedimentation  tubes 
with narrow bare extended tips (Sarstedt, Inc.) After the supernatant was 
removed,  the tips containing the pellet were amputated and counted in a 
Rack gamma counter (LKB Instruments, Inc., Galthersburg, MD). 
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formed as previously described  (28). All fibrinogen binding experiments 
were performed  in the presence of Ca  ++ (2 mM) and Mg  ++ (1 raM).  t2sI- 
Fibrinogen (3,000 cpm//zg) at a concentration  range of 10-500 #g/ml was 
incubated with the platelet suspension and additions for 5 min at 23°C. The 
platelet pellet was separated from the supemate  by centrifugation through 
a silicone oil gradient as previously described  (28).  1- 
30  I.iJ 
Calculation of  Binding Experiments  z  2a 
t~ 
Calculation of bound fibrinogen was based on the specific activities of the  O 
radiolabeled  ligand,  and  the  results  were  expressed  as  micrograms  of  ~-  24 
fibrinogen bound per 10  7 neutrophils. In a typical experiment total binding  =, 
was  the  amount  of  J25I-fibrinogen bound  in  the  absence  of unlabeled  --. 
ligand, while nonspecific binding was the amount of 125I-fibrinogen bound  r~  20 
in the presence of a 50-fold molar excess of unlabeled ligand. Specific bind-  Z 
ing  was  obtained  by  subtracting  the  nonspecific  binding  from  the  total  ::~  18  o  binding,  m  16 
In competition-inhibition  binding experiments  (50) with unlabeled  fi-  14 
brinogen,  the binding  affinity of 1251-fibrinogen was calculated  from the  Z 
IC50 using a computer program to determine the 50% inhibition point (10)  I&l  12  t.9 
as previously reported (20, 46). In concentration-dependent binding experi-  O  I 0 
ments,  the binding of Iz5I-fibrinogen to neutmphils  was analyzed  by the  Z 
graphical  method of Scatchard (45) as well as the computer programs of  ~,  8 
Munson  and Rodbard (32) and Brass and Shattil (9) using an Apple lie  m  6 
Computer  (Apple Computer  Corporation,  Cupertino,  CA). Experimental  t7  4 
results at each concentration  of ligand (both  labeled and unlabeled)  and  ! 
I-4  2  bound radioligand were entered into a preanalysis program (32) to calculate 
the  amount  of specifically bound  ligand.  The values then  were  fit to a  t~ 
Scatchard plot by a computer program developed by Brass and Shattil (9).  - 
Comparisons of experimental groups in the binding studies were performed 
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Figure 1.  Displacement of bound  ~25I-HMWK by fibrinogen from 
the neutrophil surface.  Isolated neutrophils (107/ml)  in HBSS with- 
out Ca  ++ or Mg  ++,  pH 7.4,  were incubated  with Zn  ++ (50 #M), 
Ca  ++ (2 mM),  and  125I-HMWK  (l  #g/ml) at 23°C (e).  At 8 (A) 
and  12  (m) min,  a  50-fold molar excess of unlabeled  fibrinogen 
was added. Nonspecific binding (X) was measured by 125I-HMWK 
binding in the presence of the above divalent cations and a 50-fold 
molar excess of unlabeled HMWK.  The binding was determined 
at the indicated time points as described in Materials and Methods. 
The plotted data are the mean of four experiments. 
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Figure 2. Binding of t25I-fibrinogen  to neutrophils at various tem- 
peratures.  Isolated neutrophils (107/ml)  in HBSS without Ca  ++ or 
Mg  ++, pH 7.4, were incubated with 12~I-fibrinogen (400 #g/ml) in 
the presence of Zn  ++ (50 #M) and Ca  ++ (2 mM) at 4  (A), 23 (1), 
or 37°C (t).  Simultaneously, eglin (50 #m) was added to incuba- 
tions at 23 (o) and 37°C (13) in addition to the cations and fibrino- 
gen. Nonspecific binding was determined with all the above addi- 
tions plus a  50-fold molar excess of unlabeled fibrinogen. At the 
designated time points,  samples were removed and the amount of 
~25I-fihrinogen  bound  to neutrophils was determined as  indicated 
in Materials and Methods. The plotted results are the mean +  SEM 
of three experiments where indicated. 
by the t test (paired). A difference was considered  significant at p < 0.05. 
Binding of 1251-fibrinogen and  HMWK to platelets  was analyzed  by the 
methods of Scatchard (45) and Segal (54). 
Results 
Displacement of  Bound ~2q-HMWK by ~brinogen 
from the Neutrophil Surface 
While  investigating  the  binding  of  125I-HMWK  to  neutro- 
phils, it was found that a 50-fold molar excess of fibrinogen 
could inhibit HMWK binding. Studies were conducted to de- 
termine  if  fibrinogen  could  displace  ~2SI-HMWK already 
bound to the surface of the neutrophil (Fig.  1).  12q-HMWK 
binding to neutrophils increased over time and reached a pla- 
teau by 20 min. A 50-fold molar excess of fibrinogen added 
at either 8 or  12 rain was able to displace at least 86%  of 
'2q-HMWK bound to the neutrophil surface. 
Binding of tZJl-labeled l~brinogen to Isolated Human 
Neutrophils and Effect of  Neutrophil Proteases 
Investigations  were  conducted  to  determine  whether  t2q_ 
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of neutrophils.  Binding  experiments  of  nq-fibrinogen  to 
washed neutrophils were performed at 4, 23, and 37°C (Fig. 
2). The binding of nq-fbrinogen to neutrophils at 4°C in- 
creased over time reaching a  plateau by 40-45  min  (data 
not shown). However, ~2q-fibrinogen binding at both 23 and 
37°C peaked within 1-4 min and then decreased over the next 
30 min to a  level approaching that of nonspecific binding. 
The finding that the level of nq-fibrinogen binding to the 
surface of neutrophils at 23 and 37°C decreased further after 
4  rain suggested that the ligand was proteolyzed. To deter- 
mine if the decrease in neutrophil-bound fibrinogen at later 
time points was due to proteolysis, binding studies were per- 
formed at 23 and 37°C in the presence of eglin, which in- 
hibits both of the major neutrophil proteases, cathepsin G 
and HNE. Eglin prevented the decrease in neutrophil-bound 
fibrinogen  at  both  temperatures  (Fig.  2).  This  fnding 
confirmed that proteolysis of bound fibrinogen was occur- 
ring. All subsequent binding experiments were performed at 
4°C. 
Studies were then performed to ascertain which neutrophil 
enzyme was  responsible  for the  radioligand's  proteolysis 
(Fig. 3). Proteolysis of the bound fibrinogen was evident by 
an absent Ao~ chain, as well as minimal cleavage of the BB 
chain  (Fig.  3,  lanes  1,  2,  and  4-7).  This  proteolysis of 
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Figure 4.  Effect of divalent cations on binding of nsI-fibrinogen to 
neutrophils. Isolated neutrophils ([07/ml)  in HBSS  without Ca  ++ 
or Mg  +÷, pH 7.4,  were incubated at 4°C with nsI-fibrinogen (400 
/~g/ml)  in buffer containing various cations.  In each experiment 
where an addition was made, the concentrations of Zn  +÷ and Ca  ++ 
were 50/~M and 2 raM, respectively.  At the designated time points, 
binding of n~I-fibrinogen was determined as indicated in Materials 
and Methods.  Binding was  determined  in the presence  of Zn  ÷÷ 
alone (eel  Zn  ÷+ and Ca  ++ (e),  and  Ca  ++ alone (-).  Nonspecific 
binding was measured  in the presence of all divalent cations,  ~25[_ 
fibrinogen, and a 50-fold molar excess of unlabeled fibrinogen (×). 
The plotted data are the mean  __. SEM of four experiments. 
Figure 3. Pmteolysis of nsI-fibrinogen bound to neutrophils. '251- 
Fibrinogen was incubated with neutrophils (107/ml) in the pres- 
ence of 50 ~M Zn  ++, 2 mM Ca  ++, and various inhibitors for 20 
min at 4°C, and then centrifuged through an oil mixture for 2 min. 
The pellet was solubilized in 4% SDS. The pellet and supernatant 
were run in a 7.5% polyacrylamide gel containing SDS after the 
sample was reduced by boiling for 10 min in the presence of 2% 
/~-mercaptoethanol. Lanes 1-5 contained ,~,10-fold the amount of 
radioactivity as lanes 6 and 7 and 5-fold that in lane 8. Inhibitors 
present:  none  (lane  1);  0.5  mM  leupeptin  (lane  2);  0.5  t~M 
monospecific polyclonal antibody to HNE (lane 3); 0.5 /~M soy 
bean trypsin  inhibitor (lane 4);  l  mM Foy (lane 5); none (lane 
6); 0.5 mM leupeptin (lane 7); and 0.5 ~tM eglin (lane 8). The three 
bands in lane 8 are exactly the position of the A~x, B~, and 3' chains 
in the control fibrinogen (not shown). The numbers to the left of 
the gel represent molecular mass markers in kiiodaltons. 
neutrophil-associated  fibrinogen was  only prevented by  a 
monospecific polyclonal neutralizing antibody directed to- 
ward HNE (lane 3) and eglin (lane 8). Leupeptin (lanes 2 and 
7) and soy bean trypsin inhibitor (lane 4), cysteine and serine 
protease inhibitors, respectively, and Foy (lane 5), a specific 
cathepsin G inhibitor, failed to block the proteolysis of the 
chains of bound  nq-fibrinogen.  These data  indicated that 
HNE was responsible for the proteolysis of neutrophil-bound 
~2sI-fibrinogen. 
Rote of  Divalent Cations in Fibrinogen Binding 
The  divalent  cations  required  for  the  interaction  of  ~25I- 
fibrinogen with neutrophils were determined. Since binding 
of nq-fibrinogen to platelets required extracellular Ca  ++ (7) 
and binding of nSI-HMWK to platelets (19, 20), neutrophils 
(21), and endothelial ceils (49) required Zn  ++, binding stud- 
ies were performed in the presence of these divalent cations 
(Fig. 4). Binding of ~2q-fibrinogen to neutrophils was maxi- 
mal in the presence of plasma concentrations of both Ca  ++ 
(2 raM) and Zn  ++ (50 #M).  Ca  ++ alone could not support 
nq-fibrinogen binding  to  neutrophils.  In  the  presence of 
Zn  ÷+ alone, binding was half that of the maximal level ob- 
tained  when  both  Zn  ++  and  Ca  ++  were  present.  These 
studies indicated that both Zn  ++ and Ca  ++ were required for 
optimal  binding  of  ~2q-fibrinogen  to  neutrophils.  Non- 
specifc binding was the same regardless of the absence or 
presence of any one or more divalent cations. 
To preclude the possible formation of fibrinogen aggre- 
gates in the presence of Zn  ++, we assessed the elution pat- 
The Journal of Cell Biology,  Volume 109, 1989  380 terns of fibrinogen from a size exclusion HPLC column in 
the presence and absence of this cation (Fig. 5). The elution 
patterns and predicted molecular weights were identical un- 
der both experimental conditions. Furthermore, the fibrino- 
gen peak  from the  Zn÷÷-free  Tyrode's solution,  reapplied 
to  the  column  with  Zn  ÷÷  buffer,  eluted  identically  (not 
shown). 
Specificity of Binding of Izq-Fibrinogen to Neutrophils 
To ascertain whether the binding of ~25I-fibrinogen to neu- 
trophils was  specific, we first tested the capacity of other 
proteins besides unlabeled fibrinogen to inhibit binding of 
12sI-fibrinogen to neutrophils (Table I). The binding of ~25I- 
fibrinogen to neutrophils was not inhibited by a 50-fold molar 
excess of factor XII or prekallikrein. FNDPs at a 50-fold mo- 
lar excess inhibited fibrinogen binding by 26%  (Table I), 
while a 50-fold molar excess of HMWK was able to inhibit 
the binding by 94 % (Table I). The ability of fibrinogen to in- 
hibit the binding of t2~I-fibrinogen to neutrophils was con- 
centration dependent (Fig. 6). Using the mean +  SEM for 
each point from four experiments, unlabeled fibrinogen in- 
hibited the binding of '25I-fibrinogen to neutrophils 50%  at 
a concentration of 2.8  +  1.3 #M,  which gave a calculated 
apparent  K~  of  0.49  +  0.30  #M.  This  value  was  not 
significantly different from the calculated apparent K~ ob- 
tained from the ICs0 for each individual experiment. 
Reversibility of  Binding of ~2~I-Fibrinogen 
to Neutrophils 
Binding  of JESI-fibrinogen to  neutrophils was  reversible at 
4°C  (Fig.  7).  When a  50-fold molar excess of unlabeled 
fibrinogen was added to the binding reaction at  10 and 28 
min, rapid dissociation of the bound ligand occurred with 94 
and 88 % of the bound ligand, respectively, displaced within 
1 min. Neutrophil-bound ~25I-fibrinogen also was displaced 
by a 50-fold molar excess of HMWK when added at 5 or 10 
rain (Fig.  7).  At 5 and  10 min,  82 and 77%, respectively, 
of the bound '25I-fibrinogen  was  displaced by HMWK. 
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Figure 5. Effect of Zn  ÷+ on the elution of fibrinogen from HPLC 
column.  Elution of fibrinogen (800/~g)  from TSK-4000 column 
equilibrated with Tyrode-albumin buffer free of Zn  ++ ions (  ). 
Elution of fibrinogen from TSK-4000 column equilibrated with Ty- 
rode's albumin solution containing 50 #M Zn  ÷+ (- -  -). Molecular 
mass markers are indicated with the arrows. See Material and Meth- 
ods for more explanation. 
Table L Specificity of Binding of 125I-Fibrinogen 
to Neutrophils 
~-'SI-Fibrinogen  binding 
Protein competitor*  inhibition~; 
% 
None  < 1 
Fibrinogen  100 
FNDPs  26  ±  1 
HMWK  94  ±  5 
Factor  XlI  < 1 
Prekallikrein  10  ±  4 
~2Sl-fibrinogen  (I  mg/ml,  3  uM)  was incubated for 20 rain at 4°C with hu- 
man  neutrophils (107/ml)  in  HBSS  in the presence of 50 /aM  Zn  +*,  2  mM 
Ca  ++ , and various proteins. 
* Each competitor was addexl in a  50-fold molar excess of fibrinogen. 
Values present are the mean  +  SEM of three experiments. 
Determination of the Number of  Binding Sites and 
Dissociation Constant of  Binding of'~I-Fibrinogen 
to Neutrophils 
Since at low concentrations of added fibrinogen the binding 
of '25I-fibrinogen to neutrophils was specific and reversible, 
studies were performed under equilibrium conditions to de- 
termine if binding was saturable. Increasing concentrations 
of ~25I-fibrinogen were added to neutrophils in the absence 
or presence of a  50-fold molar excess of unlabeled ligand 
(Fig.  8).  As the concentration of ~25I-fibrinogen increased, 
the level of specifc binding increased until it leveled off at 
~120 #g/ml of added  '2~I-fibrinogen (Fig.  8 B).  Using the 
graphical method of Scatchard (45), a single saturable bind- 
ing site was characterized with an apparent Kd of 0.17 ttM 
and  140,000  sites/cell (Fig.  8 A). Confirmation of this in- 
terpretation of  the graphical representation of the experimen- 
tal data was obtained by computer analysis of the same ex- 
perimental data (32).  A  plot of the computer-fitted points 
from the three individual experiments showed (Fig. 8 C) a 
sigmoid curve with a plateau at ~0.2/xM added fibrinogen. 
This result characterizes one saturable binding site with an 
apparent Kd of 0.15 ~tM. This Kd is not significantly differ- 
ent from the K, of 0.49/~M obtained by competition inhibi- 
tion analysis (Fig. 6). 
Characterization of Fibrinogen/HMWK Interaction on 
the Neutrophil Surface 
Since the binding of fibrinogen to platelets is inhibited by 
certain mAbs to the glycoprotein (GP) IIb/IIIa complex (11), 
the tetrapeptide RGDS (41), and a dodecapeptide from the 
3'  chain  of fibrinogen (T/),  the  effect of these  agents  on 
fibrinogen binding to neutrophils was investigated. The bind- 
ing of J25I-fibrinogen to  neutrophils  was  not  inhibited  by 
10E5 (an mAb to GP IIb/IIIa complex) (Table II). RGDS at 
concentrations up to 1 mM showed no inhibition (Table III). 
A second site on fibrinogen that is important for its bind- 
ing to platelet is located in the carboxy-terminal section of 
the ~/-chain. Therefore, we tested the effect of the septadeca- 
peptide CYGQQHHLGGAKQAGDV on fibrinogen binding 
to neutrophils (Table III). Although minimal inhibition was 
noted at 150 #M, at concentrations of 250-1,000/~M inhibi- 
tion ranged from 62 to 79%. 
An mAb to the OKM1 antigen on neutrophils (55) corn- 
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bigure 6.  Ability of fibrinogen  to inhibit  t25I-fibdnogen binding  to 
neutrophils.  I~I-fibdnogen (400/zg/ml) was incubated  with isolated 
neutrophils (107/ml) in the presence of HBSS without Ca  ++ or Mg  ++ 
for 20 min at 4°C in the presence of the indicated  concentration  of 
fibrinogen,  Zn  ++ (50 #M), and Ca  ++ (2 mM). The data were fit by 
a  computer program (9)  using a  four parameter logistic  function 
which calculates  the values of the ordinate  into relative  values be- 
tween 0 and 100%.  The data plotted  are the mean +  SEM of four 
experiments. 
pletely  (97%)  prevented  '2q-fibrinogen  binding  to  neutro- 
phils  (Table  II)  whereas  another  mAb  directed  against  a 
different domain of the o~ chain of CR3 (OKM10) (150/~M) 
inhibited fibrinogen binding by only 17 %. mAb IMY8 of the 
same subtype as OKM1  did not inhibit fibrinogen binding. 
Consistent  with the reciprocal  inhibition  of fibrinogen and 
HMWK binding to neutrophils,  studies also showed that the 
binding of ~2q-HMWK to neutrophils was partially inhibited 
by FNDP and not by mAb 10E5 or IMY8 (Table II). In addi- 
tion, the mAb OKM1 which completely inhibited fibrinogen 
binding did not inhibit  HMWK binding  (Table II). 
Competition kinetic binding experiments were performed 
to  determine  the  mechanism  by  which  fibrinogen  inhibits 
'25I-HMWK binding to neutrophils.  Binding of t25I-HMWK 
to neutrophils was determined in the absence or presence of 
increasing  concentrations  of fibrinogen  (data  not  shown). 
When analyzed by the method of Scatchard (45), the graph 
of  ~2SI-HMWK  binding  to  neutrophils  showed  parallel 
slopes indicating no change in K~. Increasing the fibrinogen 
concentration  decreased  the maximum number of sites for 
binding  '25I-HMWK. This result indicated that fibrinogen is 
a  noncompetitive  inhibitor  of  '25I-HMWK binding  to  the 
neutrophil  surface with an apparent K~ of 50 nM. 
Interaction of  HMWK and Fibrinogen on the 
Platelet Surface 
Since HMWK inhibited the binding of '25I-fibrinogen to ac- 
tivated neutrophils,  we investigated whether HMWK could 
also block fibrinogen binding  to platelets.  Since  Zn  ++ is a 
known requirement for HMWK binding to platelets (19, 20), 
the  effect  of  Zn  ÷÷  on  ~25I-fibrinogen  binding  to  ADP- 
stimulated platelets was studied.  Zn  ÷+ (50/zM)  alone could 
not  substitute  for Ca  r+  or  Mg  ÷+ in  the  fibrinogen-platelet 
binding studies since the number of fibrinogen binding sites 
per platelet in the presence of ADP and 50/~M  Zn  ÷+ alone 
was only 2,850 with an apparent Ko of 10 -7 M.  However, in 
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Figure  7.  Displacement of bound  '2Sl- 
fibrinogen by HMWK and unlabeled fi- 
brinogen  from the  neutrophil  surface. 
Isolated neutrophils  (107/ml) in  HBBS 
without Ca  ++ or Mg  ÷+, pH 7.4, were in- 
cubated at 4°C in the presence of Zn  ÷÷ 
(50 ttM), Ca  r÷ (2 mM), and 125I-fibrin- 
ogen (400/zg/ml).  At 5 (o) and  10 (m) 
min a 50-fold molar excess of unlabeled 
HMWK was added.  At  10 (zx) and 28 
([]) min a 50-fold molar excess of unla- 
beled  fibrinogen  was  added.  Nonspe- 
cific binding was measured in the pres- 
ence of the above additives and a 50-fold 
molar  excess  of unlabeled  fibrinogen 
(X). Binding was determined at the indi- 
cated time points as described in Mate- 
rials and Methods. The plotted data are 
the mean of three experiments. 
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Figure 8.  Concentration dependence of binding of '25I-fibrinogen 
to neutrophils.  Isolated neutrophils (PMNs) (107/1111) in I-1BSS with- 
out Ca  ++ or Mg  ++, pH 7.4,  were incubated with increasing con- 
centrations of '25I-fibrinogen (mI-FB) in the presence or absence 
of a 50-fold molar excess of unlabeled fibrinogen. B shows the total 
nonspecific and specific binding.  The figure is a representative of 
three identically performed experiments. A represents a Scatchard 
plot of the data in B.  C represents a plot of bound  '25I-fibrinogen 
(#M) on the ordinate vs. log free fibrinogen (nM) on the abscissa. 
The line running through the points represents a manual graph of 
the computer-fitted data (8) from three identically performed ex- 
periments. 
Table II. Effect of RGDS and mAbs on 125I-Fibrinogen and 
1251-HMWK Binding to Neutrophils 
~2~l-Fibrinogen  binding  '25I-HMWK binding 
Competitor  inhibition*  inhibition* 
%  % 
None  0  0  +  3 
Fibrinogen  100  86  +  2.6 
HMWK  94  +  5.0  100 
FNDPs  26  5-  1.0  22  ___ 4 
10E5  7.0  -1- 1.2  0  +  3 
OKM1  97  +  1  9.8  +  5 
OKM10  17.0  ND 
IMY8  0  0  -I- 4 
Human neutrophils (107/ml) in HBSS without Ca  ++ or Mg  +÷, pH 7.4,  were 
preincubated with each competitor in a 50-fold molar excess in the presence 
of 50/~M Zn  ++ and 2 mM Ca  ++ at 4°C for 60 rain. ~25I-Fibrinogen  (1.18 #M) 
was then added,  and binding was measured at 4°C after 30 min. 
* Values present are mean  +  SEM of three experiments. 
the  presence  of  Ca  ++  and  Mg  ++,  Zn  ++  appeared  to  sig- 
nificantly increase the number of fibrinogen binding sites on 
activated  platelets  almost  twofold  without  any  significant 
effect on the Kd (Fig. 9). Only one class of binding sites was 
detected under the experimental conditions.  It is noteworthy 
that  the  presence  of  Zn  +÷  did  not  increase  nonspecific 
fibrinogen binding  to platelets  (data not shown). 
Further studies were performed to determine the influence 
of HMWK on fibrinogen binding to activated platelets.  The 
effect of HMWK  on  ~25I-fibrinogen binding  to  ADP-stim- 
ulated platelets was studied in an incubation mixture contain- 
ing platelets,  ADP,  HMWK,  and various concentrations of 
'2q-fibrinogen (Table IV).  HMWK at a concentration of 50 
#g/ml  (plasma concentration,  80  #g/ml)  appeared  to be a 
strong inhibitor of 'zsI-fibrinogen binding to activated plate- 
lets, decreasing the number of sites sevenfold without signifi- 
cantly altering the Ka. Analysis of the data by Lineweaver- 
Burk plot showed that the inhibition of fibrinogen binding by 
HMWK was noncompetitive (data not illustrated). 
Discussion 
This study extends observations of the interaction of fibrino- 
gen and HMWK on artificial surfaces to biological surfaces 
and  demonstrates  that fibrinogen binds  to neutrophils  in a 
specific,  reversible,  and  saturable  manner.  In addition,  fi- 
Table IlL Effect of  the Peptides Derived  from Fibrinogen on 
1251-Fibrinogen Binding to Neutrophils 
Inhibition 
Concentration  CYGQQHHLGGAKQGDV  RGDS 
/~M  %  % 
50  ND  1.0 
150  17.0  ND 
250  62.0  ND 
500  71.4  4.5 
1,000  79.5  0.0 
The protocol was identical to that of Table II. The concentration of the peptides 
is  indicated.  The  inhibition is expressed as  the  mean  of two  separate ex- 
periments. 
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Figure 9.  Effect of zinc and calcium on the binding isotherm of 
~25I-fibrinogen ADP-stimulated platelets. Washed ADP-stimulated 
platelets (3  x  108/ml) in Tyrodes buffer containing Ca  ++ (2 mM) 
and Mg  +÷ (1 mM), pH 7.35, were incubated with increasing con- 
centrations of r2~I-fibrinogen. The total binding was measured in 
the presence (e) and in the absence (o) of 50 #M  ZnCI2. (X) 
Nonspecific binding of fibrinogen to nonactivated platelets in the 
presence or absence of ZnC12. A is a bindi.ng isotherm from a sin- 
gle experiment, and B represents a Scatchard plot of the specific 
binding calculated from the data in A. The correlation coefficient 
was 0.95. In five experiments the number of fibrinogen binding sites 
per platelet in the presence of Zn  ÷÷ were 52,580  +  3,040 (Kd = 
6.6 X 10  -7 M +  1.8  X 10  -7 M) and in the absence of Zn  ÷+ were 
31,200 +  4,300 (Kd =  5:2  ×  10  -7 M  +  0.7  ×  10  -7 M). 
brinogen and HMWK are able to act as reciprocal inhibitors 
on the surface of neutrophils and platelets. 
When studied by SDS-polyacrylamide gel electrophore- 
sis,  '2q-fibrinogen bound to the neutrophil surface under- 
goes proteolysis (Fig. 3), and, at 37°C, this causes a decrease 
in the surface-associated fibrinogen (Fig. 2). This proteolysis 
affects primarily the Act chain and to a lesser extent the B/~ 
chain,  resulting  in  complete disappearance of the  former 
band. The proteolysis is prevented by a monospecific, poly- 
clonal antibody directed towards HNE and by eglin but not 
by leupeptin, soybean trypsin inhibitor, or Foy, an inhibitor 
of cathepsin G. These results indicate that HNE is the major 
enzyme responsible  for this  proteolysis.  Previous  studies 
have shown that cathepsin G  and HNE in vitro can digest 
fibrinogen (36, 38). Since HNE is known to be a constituent 
of the azurophilic granules, the presence of HNE on the neu- 
trophil surface is probably the result of release during the 
preparation of the neutrophils. This proteolysis is probably 
responsible for the drop in neutrophil-bound fibrinogen ob- 
served after 4 min at 23 and 37°C, since the presence of eglin 
in the incubation mixture prevents the decrease at both tem- 
peratures. Since proteolysis affects primarily the ct chain, it 
is presumably important for the binding of ~2q-fibrinogen to 
neutrophil surface. Further studies are needed to ascertain 
the effects of fibrinogen binding to neutrophils on their cellu- 
lar metabolism. Since HNE is liberated during blood coagu- 
lation (39) and digests fibrinogen to release a fragment con- 
mining fibrinopeptide A  (63),  proteolysis of fibrinogen in 
vivo could occur to possibly regulate the extent of thrombus 
formation on or about the neutrophil surface. Weitz et al. 
(64)  /  recently  proposed  that  neutrophils  migrating  on  a 
fibrinogen-coated surface form zones of close contact with 
fibrinogen, thus preventing the access of plasma protease in- 
hibitors to HNE released at or near the surface interface. 
The binding of fibrinogen to platelets requires the presence 
of Ca  ++  since, this divalent cation is necessary for the as- 
sociation of GP IIb and IIIa, which when in complex, func- 
tion as the fibrinogen receptor on the platelet surface (31). 
The amount of 'zq-fibrinogen bound to the activated platelet 
surface is  increased if physiologic concentrations of Zn  ÷+ 
are present in addition to the Ca  ++ (Table III). An increase 
of fibrinogen binding sites on the surface of neutrophils or 
platelets by Zn  ++ may result from an effect on fibrinogen 
(29) or from the direct action of this cation on the cell surface 
receptors. In support of the former explanation, it is known 
that fibrinogen will bind to a zinc affinity column (52). How- 
ever, our data demonstrate that Zn  ++ at the concentrations 
used in this study did not cause fibrinogen aggregates (Fig. 
5). Therefore, we consider the latter explanation. The mech- 
anism of the Zn  ++ action on the cell surface is unknown; it 
has been recently reported that Zn  ++ stabilizes platelet cyto- 
skeleton by preventing proteolysis of structural elements (68) 
and that it enhances protein tyrosine kinase activity of  human 
platelet membranes (15). The relevance of these observations 
for the unmasking of spare fibrinogen receptors might ex- 
plain the observation that the number of GP IIb/IIIa complex 
antigenic sites detected by certain mAbs to GP IIb/IIIa is 
higher than the number of fibrinogen binding sites exposed 
by ADP (35). 
The divalent cation requirements for the binding of J25I- 
fibrinogen to the neutrophil surface were different from those 
of the platelet surface. Both Zn  ++ and Ca  ++ were required 
for optimal binding (Figs. 4 and 10) for both cells. However, 
in contrast to platelets,  if Ca  ++ alone is used,  the level of 
fibrinogen binding to neutrophils is not greater than nonspe- 
cific binding. Binding to neutrophils occurs in the presence 
Table IV.  Effect of HMWK on 125I-Fibrinogen Binding 
to Platelets 
Control platelet  Platelet  suspension 
suspension  with HMWK 
Kd  6.65 +  1.8  6.38 ::t: 1.4 (10  -7  M) 
n  52,580 -t- 3,040  7,200 +  3,600 
400 #1 of platelet suspension was incubated for 5 min at 22°C with 10 #1 of 
~2Sl-fibrinogen (16-400 #g),  10 tzl ADP (60 tzM),  Ca  ++ (2 mM final  concen- 
tration),  and Zn  ++ (50 #M)  without or with HMWK (50 #g/ml).  Scatchard 
analysis  was  used  to  determine  K~  and  number of binding  sites  (n).  The 
values represent the mean  ±  SEM of five experiments. 
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of the optimal binding in presence of both cations. 
The binding of fibrinogen to the platelet GP IIb/IIIa com- 
plex has been demonstrated to be inhibited by mAbs, such 
as 10E5, against the heterodimer complex (11) as well as by 
the adhesive tetrapeptide RGDS (41). The sequence RGD, 
which is a recognition site for certain integrins (42), is pres- 
ent in the fibrinogen molecule at two separate sites (62) and 
appears to be important in cell binding (17). The dodecapep- 
tide for the carboxy terminal of the 3" chain is also important 
(27).  ~25I-fibrinogen  binding to neutrophils, however,  is not 
inhibited by the mAb 10E5 or by the adhesive peptide RGDS. 
Moreover,  RGD  is  also  present  in  fibronectin  (37) but 
FNDPs, which are known to stimulate neutrophils (59) and 
recognize macrophages (62, 63), only weakly inhibit fibrin- 
ogen binding to neutrophils (Table II). In contrast, the sep- 
tadecapeptide derived from the fibrinogen 3' chain did inhibit 
fibrinogen binding to  neutrophils at concentrations  >/250 
#M. This finding suggests that the 3' chain plays a role in the 
interaction with CR3 on the neutrophil surface similar to its 
interaction with the integrin GP lib on the platelet surface. 
We tested two mAbs (OKM1 and OKM10) directed toward 
different epitopes (13) on the a  chain of CR3 for their effect 
on J25I-fibrinogen binding to neutrophils.  The heterodimer 
complex recognized by OKM1 and OKM10 is one of a family 
of human leukocyte differentiation antigens with distinct a 
subunits and a common/~ subunit which include the lympho- 
cyte function-associated antigen (LFA-1), CR3,  or Mac-l, 
and the  P150,95  molecule  (44).  Recent epitope  mapping 
studies have shown that CR3 is a multivalent receptor (65, 
66) with at least two independent adhesion-related functions; 
one is identified by OKM1  and the other by OKM10 (13). 
OKM1 has a functional domain which is involved with such 
neutrophil functions as aggregation (13), spreading on plas- 
tic surfaces (4), and chemotaxis (13). Most recently Wright 
et al. (67) studied the adhesion of neutrophil to fibrinogen- 
coated surfaces. In agreement with our data, this reaction 
was not affected by mAbs directed against GP IIb/IIIa com- 
plex or by RGD-derived peptides and was inhibited by the 
carboxy-terminal peptide of the fibrinogen 3, chain.  How- 
ever, neutrophil adherence to surface-bound fibrinogen was 
inhibited by OKM10 and was not inhibited by OKM1. In our 
studies OKM1  completely inhibited the binding of I25I-fi- 
brinogen to neutrophils while OKMI0 resulted in only 17 % 
inhibition. Our results differ from those of Weitz et al. (64), 
but any difference in results could be explained by the fact 
that their system used surface-adsorbed fibrinogen and no di- 
rect binding studies, while our experiments were direct bind- 
ing studies done in a  fluid phase.  The difference between 
surface-bound  fibrinogen  and  fluid-phase  fibrinogen  has 
been studied with respect to platelet adhesion. Lindon et al. 
(29)  have demonstrated that the reaction of platelets with 
surface-bound fibrinogen correlated with the quantity of an- 
tigenic fibrinogen but not with total fibrinogen adsorbed, im- 
plying a conformational change upon binding. 
Our results do agree with those of Altieri et al.  (3) who 
demonstrated that neither OKM10 nor RGD-containing syn- 
thetic peptide inhibited binding of fibrinogen to monocytes. 
In addition Altieri et al. have previously shown that binding 
of fibrinogen to monocytes is inhibited by OKM1 (2).  These 
leukocyte differentiation antigens are  part  of the  integrin 
receptor super family (23, 40, 44).  We found that there are 
140,000 sites for fibrinogen on the neutrophil, in agreement 
with Springer et al. (56) who found 140,000 binding sites on 
Mac-l, consistent with our hypothesis that CR3 (C1 lb/CD18) 
of human  neutrophils  functions as  a  fibrinogen receptor 
through an RGD-independent mechanism. The data by AI- 
tieri et al. (3) suggest that the same mechanism operates dur- 
ing the interaction of  monocytes with fibrinogen. At the pres- 
ent  stage  of knowledge,  it  is  difficult to  extrapolate  our 
experimental data to an in vivo situation. Since the plasma 
fibrinogen exceeds the affinity for fibrinogen to bind to neu- 
trophils,  it is possible that all fibrinogen receptors on the 
neutrophils are occupied under physiological conditions in 
the flowing blood. 
Fibrinogen and HMWK can displace each other from the 
surface  of the  neutrophil  (Figs.  1  and  7).  Furthermore, 
HMWK functions as an inhibitor of fibrinogen binding on 
the  surface of the activated platelet  (Table  III).  Previous 
studies showed that fibrinogen did not inhibit ~25I-HMWK 
binding to unstimulated platelets (23).  Activation of platelets 
may initiate membrane changes that allow HMWK to com- 
pete with fibrinogen. Our own studies may have been per- 
formed with neutrophils that were partially activated in the 
course of isolation. To begin to address this question, neutro- 
phils were stimulated with phorbol myristate acetate (1 ~tM); 
these neutrophils released significant levels of elastate com- 
pared  to  resting  cells  and  bound three-  to  fivefold more 
fibrinogen than the resting cells. Further studies are needed 
to characterize the mechanism of this additional receptor 
exposure. 
The finding that upon binding to neutrophils fibrinogen is 
proteolyzed by elastase suggested that this granule enzyme 
may have adsorbed to the neutrophil before binding of fibrin- 
ogen to the cell surface. Since the inhibition of ~25I-HMWK 
binding to neutrophils by fibrinogen (Table II) and ~25I-fibrin- 
ogen binding to platelets by HMWK (Table IV) are noncom- 
petitive, fibrinogen and HMWK probably do not share the 
same receptor(s) on either the neutrophil or platelet surface. 
This interpretation is reinforced by the results obtained from 
the experiments with various mAbs. An mAb, 10E5, to the 
GP IIb/IIIa complex inhibits binding of fibrinogen to the 
platelet surface but does not inhibit the binding of HMWK 
to platelets (our unpublished observation), while the mAb, 
OKM1 inhibits binding of fibrinogen to the neutrophil surface 
but does not inhibit binding of HMWK (Table II). The in- 
hibitory effect of HMWK on the binding of fibrinogen to 
platelets and neutrophils may result form steric hindrance 
since both HMWK and fibrinogen are large asymmetric pro- 
teins.  It is  likely that the fibrinogen and HMWK binding 
sites, while distinct, are closely located on the platelet and 
neutrophil membrane. 
The  functional  significance  of  ~25I-HMWK binding  to 
neutrophils is not fully understood. In other studies (21) we 
have demonstrated that neutrophil activation induced by kal- 
likrein required the presence of HMWK,  since a  patient 
deficient in HMWK in both neutrophils (21) and plasma (12) 
exhibited  no  HNE  release  after  contact  activation.  This 
patient's neutrophils function normally in normal plasma. 
Although the functional significance of binding of ~25I-fibrin- 
ogen to neutrophils is not completely elucidated, our demon- 
stration that binding of fibrinogen is inhibited by an mAb to 
CR3 suggests that fibrinogen may play a role in such neutro- 
phil  functions such as aggregation (2),  spreading on sur- 
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Mac-l, LFA-1, and Leu M5 leukocyte-deficiency syndrome 
(4) is characterized by recurrent bacterial and fungal infec- 
tions, delayed umbilical cord separations, poor wound heal- 
ing,  and an impaired inflammatory response,  suggests pos- 
sible  pathological  implications  for  fibrinogen  binding  to 
neutrophils.  Human  fibrinopeptide  B,  a  thrombin-derived 
proteolytic cleavage product of the fibrinogen B chain,  has 
been  demonstrated  to  cause  neutrophil  chemotaxis  (25). 
Further studies have shown that this chemotactic effect oc- 
curs in the absence of degranulation,  aggregation, or super- 
oxide production, and does not involve the neutrophil recep- 
tor  for  C5a,  N-formyl-methionyl-leucyl-phenylalanine,  or 
LTB4 (55).  Thus,  elastase-catalyzed fibrinogen  derivatives 
bound to the neutrophil surface may function in the recruit- 
ment of neutrophils  to the area of inflammation. 
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